Bengt Westermark
Direttore/Membro del Consiglio presso MEDIVIR AB
Patrimonio netto: 9 828 $ in data 31/05/2024
Posizioni attive di Bengt Westermark
Società | Posizione | Inizio | Fine |
---|---|---|---|
MEDIVIR AB | Direttore/Membro del Consiglio | 01/01/2017 | - |
Independent Dir/Board Member | 01/01/2017 | - | |
University of Uppsala | Corporate Officer/Principal | 01/01/1986 | - |
Royal Swedish Academy of Sciences
Royal Swedish Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Sciences provides research and development services on sciences. The non-profit company is based in Stockholm, Sweden. | Corporate Officer/Principal | - | - |
Direttore/Membro del Consiglio | - | - | |
European Molecular Biology Organization | Corporate Officer/Principal | - | - |
Direttore/Membro del Consiglio | - | - | |
Royal Society of Sciences | Corporate Officer/Principal | - | - |
The European Academy of Cancer Sciences
The European Academy of Cancer Sciences Miscellaneous Commercial ServicesCommercial Services The European Academy of Cancer Sciences is an independent advisory body of medical specialists and researchers. The Swedish company's mission is to create a continuum of cancer research, from basic research to evidence-based cancer care and prevention. The private company provides evidence-based advice to inform policy and organize their work through scientific committees gathered around priority areas across the cancer spectrum. The Academy has consulted a wide range of cancer research, policy, and care specialists and patient organizations to formulate consensus advice to the cancer mission board. The company reached the consensus view that a comprehensive translational cancer research approach that is focused on personalized/precision medicine and that covers the entire cancer research, cancer care, and prevention continuum has the potential to achieve in 2030 the goal of a 10-year cancer-specific survival for 75%% of the patients diagnosed with cancer in EU member states with a well-developed healthcare system. | Corporate Officer/Principal | - | - |
Direttore/Membro del Consiglio | - | - |
Storia della carriera di Bengt Westermark
Precedenti posizioni note di Bengt Westermark
Società | Posizione | Inizio | Fine |
---|---|---|---|
MEDIVIR AB | Direttore/Membro del Consiglio | 03/05/2017 | 05/05/2021 |
Independent Dir/Board Member | 03/05/2017 | 05/05/2021 | |
The Swedish Cancer Society | Corporate Officer/Principal | 01/01/2003 | 01/01/2013 |
HAMLET PHARMA AB (PUBL) | Direttore/Membro del Consiglio | - | - |
Statistiche
Distribuzione geografica
Svezia | 8 |
Germania | 2 |
Posizioni
Director/Board Member | 6 |
Corporate Officer/Principal | 6 |
Independent Dir/Board Member | 2 |
Settori
Health Technology | 3 |
Commercial Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
HAMLET PHARMA AB (PUBL) | Health Technology |
MEDIVIR AB | Health Technology |
Aziende private | 5 |
---|---|
Royal Swedish Academy of Sciences
Royal Swedish Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Sciences provides research and development services on sciences. The non-profit company is based in Stockholm, Sweden. | Commercial Services |
European Molecular Biology Organization | |
Royal Society of Sciences | |
The Swedish Cancer Society | |
The European Academy of Cancer Sciences
The European Academy of Cancer Sciences Miscellaneous Commercial ServicesCommercial Services The European Academy of Cancer Sciences is an independent advisory body of medical specialists and researchers. The Swedish company's mission is to create a continuum of cancer research, from basic research to evidence-based cancer care and prevention. The private company provides evidence-based advice to inform policy and organize their work through scientific committees gathered around priority areas across the cancer spectrum. The Academy has consulted a wide range of cancer research, policy, and care specialists and patient organizations to formulate consensus advice to the cancer mission board. The company reached the consensus view that a comprehensive translational cancer research approach that is focused on personalized/precision medicine and that covers the entire cancer research, cancer care, and prevention continuum has the potential to achieve in 2030 the goal of a 10-year cancer-specific survival for 75%% of the patients diagnosed with cancer in EU member states with a well-developed healthcare system. | Commercial Services |
- Borsa valori
- Insiders
- Bengt Westermark
- Esperienza